• 1
    Lubel J, Testro A, Angus P. Hepatitis B reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J 2007; 37: 70512.
  • 2
    Iannitto E, Minardi V, Calvaruso G, Ammatuna E, Florena AM, Mule A, et al. Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haematol 2005; 74: 2548.
  • 3
    Yang CH, Wu TS, Chicu CT. Chronic hepatitis B reactivation: a word of caution regarding the use of systemic glucocorticosteroid therapy. Br J Dermatol 2007; 3: 58790.
  • 4
    Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab [letter]. N Engl J Med 2001; 344: 689.
  • 5
    Tsai FC, Hsieh SC, Chen DS, Sheu JC, Chen CH. Reactivation of hepatitis B virus in rheumatologic patients receiving immunosuppressive agents. Dig Dis Sci 2006; 51: 162732.
  • 6
    Ito S, Nakazono K, Murasawa A, Mita Y, Hata K, Saito N, et al. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum 2001; 44: 33942.
  • 7
    Narvaez J, Rodriguez-Moreno J, Martinez-Aguila MD, Clavaguera MT. Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy [letter]. J Rheumatol 1998; 25: 20378.
  • 8
    Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for adult onset Still's disease. J Rheumatol 2003; 30: 16245.
  • 9
    Oniankitan O, Duvoux C, Challine D, Mallat A, Chevalier X, Pawlotsky JM. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 2004; 31: 1079.
  • 10
    Hagiyama H, Kubota T, Komano Y, Kurosaki M, Watanabe M, Miyasaka N. Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis [review]. Clin Exp Rheumatol 2004; 22: 3756.
  • 11
    Yeo W, Chan PK, Ho WM, Zee B, Lam KC, Lei KI. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004; 22: 92734.
  • 12
    Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich KC, Young RC, et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982; 96: 4479.
  • 13
    Lok A, Lai C. Acute exacerbations in Chinese patients with chronic hepatitis: incidence, predisposing factors and etiology. J Hepatol 1990; 10: 2934.
  • 14
    Khokhar OS, Farhadi A, McGrail L, Lewis JH. Oncologists and hepatitis B: a survey to determine current level of awareness and practice of antiviral prophylaxis to prevent reactivation. Chemotherapy 2009; 55: 6975.
  • 15
    Thong B, Koh ET, Chng HH, Chow WC. Outcomes of chronic hepatitis B infection in oriental patients with rheumatic diseases. Ann Acad Med Singapore 2007; 36: 1005.
  • 16
    Vassilopoulos D, Calabrese LH. Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections. Curr Opin Rheumatol 2007; 19: 61925.
  • 17
    Pavy S, Constantin A, Pham T, Gossec L, Maillefert JF, Cantagrel A, et al. Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 2006; 73: 38895.
  • 18
    Mok MY, Ng WL, Yuen MF, Wong RW, Lau CS. Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin Exp Rheumatol 2000; 18: 3638.
  • 19
    Flowers MA, Heathcote J, Wanless IR, Sherman M, Reynolds WJ, Cameron RG, et al. Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy. Ann Intern Med 1990; 112: 3812.
  • 20
    Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumor necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B and HIV infection. Ann Rheum Dis 2004; 63: ii1824.
  • 21
    Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate [letter]. Ann Rheum Dis 2003; 62: 6867.
  • 22
    Wendling D, Auge B, Bettinger D, Lohse A, Le Huede G, Bresson-Hadni S, et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy [letter]. Ann Rheum Dis 2005; 64: 7889.
  • 23
    Loomba R, Rowley AK, Wesley R, Smith KG, Liang TJ, Pucino F, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148: 51928.
  • 24
    Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B (HBV) virus reactivation with immunosuppressive therapy in rheumatic diseases: assessment and prevention strategies. Ann Rheum Dis 2006; 65: 9839.
  • 25
    Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 76284.
  • 26
    Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008; 57: 120.
  • 27
    Goldstein ST, Alter MJ, Williams IT, Moyer LA, Judson FN, Mottram K, et al. Incidence and risk factors for acute hepatitis B in the United States, 1982–1998: implications for vaccination programs. J Infect Dis 2002; 185: 7139.
  • 28
    Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 50739.
  • 29
    Cacoub P, Saadoun D, Bourliere M, Khiri H, Martineau A, Benhamou Y, et al. Hepatitis B virus genotypes and extrahepatic manifestations. Hepatology 2005; 43: 76470.
  • 30
    Cesur S, Akin K, Albayrak F, Birengel S, Kurt H, Balik I. Prevalence of extrahepatic illnesses in patients with chronic hepatitis b and hepatitis c: retrospective study of 435 patients. Mikrobiyol Bul 2003; 37: 18793. In Turkish.
  • 31
    Guennoc X, Narbonne V, Jousse-Joulin S, Devauchelle-Pensec V, Dougados M, Daures JP, et al. Is screening for hepatitis B and hepatitis C useful in patients with recent-onset polyarthritis? The ESPOIR cohort study. J Rheumatol 2009; 36: 140713.
  • 32
    Kohrt H, Ouyang D, Keeffe E. Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B infection. Clin Liver Dis 2007; 11: 96591.
  • 33
    Kim JS, Hahn JS, Park SY, Kim Y, Park IH, Lee CK, et al. Long-term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in non-Hodgkin's lymphoma. Yonsei Med J 2007; 48: 7889.
  • 34
    Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009; 49: 150314.
  • 35
    Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 244255.
  • 36
    Charbel H, Lewis JH. Hepatitis B reactivation during chemotherapy and other immunosuppresion. In: ShettyK, WuG, editors. Chronic viral hepatitis. 2nd ed. Totowa (NJ): Humana Press; 2009.
  • 37
    Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6: 131541.
  • 38
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 174351.
  • 39
    Sheehan KB. E-mail survey response rates: a review. Journal of Computer-Mediated Communication 2001. URL:
  • 40
    Keeter S, Kohut A, Miller A, Groves R, Presser S. Consequences of non-response in a large national telephone survey. Publ Opin Q 2000; 64: 12548.
  • 41
    Han SH. Extrahepatic manifestations of chronic hepatitis B [review]. Clin Liv Dis 2004; 8: 40318.
  • 42
    Aprosina ZG, Serov VV, Krel' PE, Ignatova TM. Extrahepatic manifestations of chronic viral liver disease [review]. Arkh Patol 1999; 61: 515. In Russian.